JoVE - Journal of Visualized Experiments
JoVE Visualize
Contact Us

Psychosis metabolic risk calculator (PsyMetRiC) in early psychosis: External validation study in Finland

  • 0Mental Health Team, Department of Public Health and Welfare, Finnish Institute for Health and Welfare, Helsinki, Finland.
Acta Psychiatrica Scandinavica +

|

August 29, 2024

|

August 29, 2024

View abstract on PubMed

Summary

This summary is machine-generated.

The psychosis metabolic risk calculator (PsyMetRiC) accurately predicts cardiometabolic risk in early psychosis patients. This tool offers superior risk prediction and clinical utility compared to general population scores.

Area Of Science

  • Psychiatry
  • Cardiology
  • Metabolic Health

Background

  • Early psychosis increases cardiometabolic morbidity and mortality.
  • Accurate risk assessment is vital for timely intervention in psychotic disorders.
  • The psychosis metabolic risk calculator (PsyMetRiC) was developed for UK youth with psychosis.

Purpose Of The Study

  • To externally validate the PsyMetRiC tool in a Finnish early psychosis cohort.
  • To compare the predictive accuracy and clinical usefulness of PsyMetRiC against the Finnish Diabetes Risk Score (FINDRISC).

Main Methods

  • Validation of PsyMetRiC (full and partial models) and FINDRISC in 278 patients (18-35 years) with first-episode or ultra-high-risk for psychosis.
  • Assessment of discrimination (C-statistic), calibration, and clinical usefulness (decision curve analysis).
  • Site-specific recalibration of PsyMetRiC (PsyMetRiC-Fi) was performed.

Main Results

  • PsyMetRiC's full model showed marginally better discrimination (C=0.72) than its partial model (C=0.70) and FINDRISC (C=0.63).
  • PsyMetRiC demonstrated minor miscalibration, which was corrected after recalibration; FINDRISC showed more pronounced miscalibration.
  • Decision curve analysis indicated PsyMetRiC's clinical usefulness in managing cardiometabolic risk in early psychosis.

Conclusions

  • PsyMetRiC is a valuable tool for predicting cardiometabolic risk in Finnish early psychosis patients.
  • PsyMetRiC offers superior discriminatory accuracy and risk prediction compared to FINDRISC.
  • The recalibrated PsyMetRiC-Fi enhances its utility for clinical application in this population.

Keywords: